Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.67 |
| ▸ | DRD2 | P14416 | 9/20 | 0.67 |
| ▸ | LTA4H | P09960 | 2/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 2/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781392 | 1.00 | DRD4 (0.67) | DRD4DRD2LTA4HMCHR1SIGMAR1 | |
| SCHEMBL7393471 | 1.00 | DRD4 (0.67) | DRD4DRD2LTA4HMCHR1SIGMAR1 | |
| SCHEMBL11949312 | 0.92 | DRD2 (0.57) | DRD4DRD2LTA4HMCHR1DPP7 | |
| SCHEMBL16007156 | 0.92 | DRD2 (0.57) | DRD4DRD2LTA4HMCHR1DPP7 | |
| SCHEMBL7374896 | 0.91 | DRD2 (0.55) | DRD4DRD2LTA4HMCHR1SIGMAR1 | |
| SCHEMBL3164487 | 0.91 | SIGMAR1 (0.74) | DRD4DRD2MCHR1SIGMAR1DPP7 | |
| SCHEMBL7600259 | 0.91 | DPP7 (0.56) | DRD4DRD2LTA4HMCHR1DPP7 | |
| SCHEMBL239527 | 0.90 | DRD4 (0.71) | DRD4DRD2MCHR1SIGMAR1BACE1 | |
| SCHEMBL239528 | 0.90 | DRD4 (0.71) | DRD4DRD2MCHR1SIGMAR1BACE1 | |
| SCHEMBL17961749 | 0.88 | DRD4 (0.70) | DRD4DRD2MCHR1SIGMAR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-3277682-B1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2019-04-24 | — | — | EP | disclosed |
| US-10174035-B2 | 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180072732-A1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072732-A1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| WO-2016157074-A1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-06 | — | — | WO | disclosed |
| EP-2097374-B1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | SANOFI AVENTIS (FR) | 2010-06-09 | — | — | EP | disclosed |
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
| WO-2008087278-A2 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | disclosed |
| EP-0723545-B1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LAB (US) | 2002-05-08 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0302372-B1 | NAPHTHYRIDINE ANTIANAEROBIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1992-12-16 | — | — | EP | disclosed |
| EP-0302372-A1 | Naphthyridine antianaerobic compounds | ABBOTT LABORATORIES (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174035-B2 | 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors | PIK3CA, AKT3, AKT2 | DRD4 2152/4885DRD2 1305/4885LTA4H 1996/4885 |
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | AVPR2, AVPR1A, AVPR1B | DRD4 261/4885DRD2 158/4885LTA4H 2317/4885 |
| US-20180072732-A1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | PIK3CA, AKT3, AKT2 | DRD4 2152/4885DRD2 1305/4885LTA4H 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.